Breast Cancer Therapeutics Market by Drug Classes – Brand Name (Chemical Name) – Antimetabolites – Gemzar (Gemcitabine), Aromatase Inhibitors – Afinitor (Everolimus), Arimidex (Anastrozole), Aromasin (Exemestane), Femara (Leterozole), Ibrance (Palbociclib); Her2 Inhibitors – Herceptin (Trastuzumab), Kadcyla (Ado-Trastuzumab Emtansine), Perjeta (Pertuzumab), Tykerb (Lapatinib); Hormone Receptors –  Fareston, Faslodex, Zoladex; and Mitotic Inhibitors – Halaven (Eribulin), Ixempra (Ixabepilone), Taxotere (Docetaxel) and Forecast 2017-2021

Breast Cancer Therapeutics Market by Drug Classes – Brand Name (Chemical Name) – Antimetabolites – Gemzar (Gemcitabine), Aromatase Inhibitors – Afinitor (Everolimus), Arimidex (Anastrozole), Aromasin (Exemestane), Femara (Leterozole), Ibrance (Palbociclib); Her2 Inhibitors – Herceptin (Trastuzumab), Kadcyla (Ado-Trastuzumab Emtansine), Perjeta (Pertuzumab), Tykerb (Lapatinib); Hormone Receptors –  Fareston, Faslodex, Zoladex; and Mitotic Inhibitors – Halaven (Eribulin), Ixempra (Ixabepilone), Taxotere (Docetaxel) and Forecast 2017-2021

Breast cancer therapeutics include hormone therapies, signal transduction inhibitors, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, and toxin delivery molecules. Breast cancer is the most common type of invasive cancer affecting women, and it is the most common cause of cancer death among women worldwide. It usually originates from the inner lining of milk ducts or lobules responsible for supplying the milk. The malignant type of tumor can spread to other cells present in the body. North America dominates market share for breast cancer therapeutics considering highest prevalence rate, modern medical technologies, health insurance coverage, and optimum per capita income.

The global breast cancer therapeutics market report estimates the market size (Revenue USD million – 2014 to 2021) for key market segments based on the drug classes – brand name (chemical name) such as antimetabolites – Gemzar (gemcitabine), aromatase inhibitors – Afinitor (everolimus), Arimidex (anastrozole), Aromasin (exemestane), Femara (leterozole), Ibrance (palbociclib); Her2 Inhibitors – Herceptin (trastuzumab), Kadcyla (ado-trastuzumab emtansine), Perjeta (pertuzumab), Tykerb (lapatinib); Hormone receptors –  Fareston, Faslodex, Zoladex; and Mitotic inhibitors – Halaven (eribulin), Ixempra (ixabepilone), Taxotere (docetaxel), and forecasts growth trends (CAGR% – 2017 to 2021).

The global breast cancer therapeutics market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global breast cancer therapeutics market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

Major players operating in the global breast cancer therapeutics market and included in this report are AstraZeneca plc, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc., Puma Biotechnology, Sanofi S.A., Teva Pharmaceutical Industries Ltd.

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue USD Million, 2014-2021)
    • Forecast Estimation (Revenue USD Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2025)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Breast Cancer Therapeutics Market

1. Drug Class
1.1. Anti-metabolites
1.1.1. Gemzar (Gemcitabine)
1.2. Aromatase Inhibitors
1.2.1. Afinitor (Everolimus)
1.2.2. Arimidex (Anastrozole)
1.2.3. Aromasin (Exemestane)
1.2.4. Femara (Leterozole)
1.2.5. Ibrance (Palbociclib)
1.3. HER2 Inhibitors
1.3.1. Herceptin (Trastuzumab)
1.3.2. Kadcyla (Ado-trastuzumab emtansine)
1.3.3. Perjeta (Pertuzumab)
1.3.4. Tykerb (Lapatinib)
1.4. Hormone Receptor
1.4.1. Fareston
1.4.2. Faslodex
1.4.3. Zoladex
1.5. Mitotic Inhibitors
1.5.1. Halaven (Eribulin)
1.5.2. Ixempra (Ixabepilone)
1.5.3. Taxotere (Docetaxel)

2. Company Profiles
2.1. AstraZeneca plc
2.2. Eisai Co., Ltd.
2.3. Eli Lilly and Company
2.4. F. Hoffmann-La Roche Ltd.
2.5. GlaxoSmithKline plc
2.6. Novartis International AG
2.7. Pfizer, Inc.
2.8. Puma Biotechnology, Inc.
2.9. Sanofi S.A.
2.10. Teva Pharmaceutical Industries Ltd.

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*

Translate »